NeuroSense Therapeutics

Sector: Biotechnology: Pharmaceutical Preparations

About NeuroSense Therapeutics

NeuroSense Therapeutics (Nasdaq: NRSN) is a clinical-stage biotech firm specializing in severe neurodegenerative diseases. In Q1 2026, the company is preparing to release critical clinical and biomarker results for its lead candidate, PrimeC, which aims to slow ALS progression by targeting multiple disease mechanisms simultaneously.